Cipla is developing a biosimilars pipeline, with plans to add 1-2 products yearly for the next five years. The drugmaker is investing in R&D, especially for developed markets, to build out a strong pipeline across respiratory, peptides as well as complex … For the full story, visit the source.
Business
Cipla bets on fast-growing biosimilars market, to steadily add products: CEO
Cipla is developing a biosimilars pipeline, with plans to add 1-2 products yearly for the next five years. The drugmaker is investing in R&D, especially for developed markets, to build out a strong pipeline across respiratory, peptides as well as complex …
By Jessica Jani· Livemint· 1 day ago· 2 min read
This summary is sourced from Livemint. Read the full article at:Livemint